(Dec 7, 2018) The CSPCP responded to a commentary in the CMAJ asking for a ministerial recall of high-strength opioid formulations. Thank you to CSPCP Communications Committee Member Catriona Aparicio for helping prepare the response.
The Quality End of Life Coalition of Canada (QELCCC) hosted a breakfast for MPs in Ottawa on October 25th. Several CSPCP members and Board members mixed and mingled with the crowd, which included MPs, senators, and representatives from many of the QELCCC member organizations. A highlight of the event was a moving personal story shared by Paul Adams. To view an earlier written version of the story, click here.
(Update: August 2018) Novartis/Alcon will not discontinue the sale of Atropine 1% as they had previously announced. The decision came after consideration of the joint letter that was sent in May 2018 (below).
(May 2018) The Canadian Ophthalmological Society, the Canadian Psychiatric Association, and the CSPCP sent a joint letter to Novartis/Alcon, urging them to reconsider the upcoming discontinuation of Atropine.
The CSPCP recommends that education (such as the Methadone4Pain course from Canadian Virtual Hospice) should be mandated in each province or territory as a criterion for prescribing Methadone. The CSPCP sent letters to the federal, provincial and territorial Ministers of Health and to provincial and territorial regulatory bodies.
In April 2018, the CSPCP joined the Ontario Medical Association and six other organizations to advocate for Dan’s Law – which seeks to remove the three-month waiting period for access to OHIP-funded palliative care and home care for Canadian residents who move to or return to Ontario. Ontario has now indicated that changes will be made to OHIP to allow for this. Hopefully other provinces will follow suit. Huge thanks to Dr. Darren Cargill for garnering widespread support for this bill.